↓ Skip to main content

Cochrane Database of Systematic Reviews

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria

Overview of attention for article published in Cochrane database of systematic reviews, October 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

news
1 news outlet
twitter
12 tweeters
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
165 Mendeley
Title
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
Published in
Cochrane database of systematic reviews, October 2014
DOI 10.1002/14651858.cd010340.pub2
Pubmed ID
Authors

Arturo J Martí-Carvajal, Vidhu Anand, Andrés Felipe Cardona, Ivan Solà

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic, not malignant, disease of the hematopoietic stem cells, associated with significant morbidity and mortality. It is a rare disease with an estimated incidence of 1.3 new cases per one million individuals per year. The treatment of PNH has been largely empirical and symptomatic, with blood transfusions, anticoagulation, and supplementation with folic acid or iron. Eculizumab, a biological agent that inhibits complement cascade, was developed for preventing hemolytic anemia and severe thrombotic episodes.

Twitter Demographics

The data shown below were collected from the profiles of 12 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 165 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 165 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 40 24%
Researcher 23 14%
Student > Doctoral Student 16 10%
Student > Ph. D. Student 14 8%
Student > Bachelor 13 8%
Other 30 18%
Unknown 29 18%
Readers by discipline Count As %
Medicine and Dentistry 67 41%
Nursing and Health Professions 18 11%
Pharmacology, Toxicology and Pharmaceutical Science 10 6%
Psychology 7 4%
Agricultural and Biological Sciences 6 4%
Other 25 15%
Unknown 32 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 April 2020.
All research outputs
#1,240,712
of 17,520,458 outputs
Outputs from Cochrane database of systematic reviews
#3,205
of 11,710 outputs
Outputs of similar age
#19,346
of 240,262 outputs
Outputs of similar age from Cochrane database of systematic reviews
#87
of 251 outputs
Altmetric has tracked 17,520,458 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,710 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.2. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,262 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 251 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.